Roche says comparison study for its Gazyva/ Gazyvaro showed superior progression-free survival in follicular lymphoma
Roche (SIX: ROG) on Friday said late-stage comparison trials for its drug to treat a slower form of non-Hodgkin lymphoma showed significant progression-free survival over the other treatment.
The results showed that Gazyva/ Gazyvaro-based treatment significantly reduced the risk of disease worsening or death compared to MabThera/ Rituxan-based treatment.
The comparison study tested the efficacy and safety of Gazyva/Gazyvaro (obinutuzumab) plus chemotherapy followed by Gazyva/Gazyvaro alone, head-to-head with MabThera/Rituxan (rituximab) plus chemotherapy followed by MabThera/Rituxan alone.
Sandra Horning, chief medical officer said: “People with follicular lymphoma continue to need better initial treatment options because their disease is incurable and becomes more difficult to treat with each relapse. Gallium is the second study in which Gazyva/Gazyvaro showed superior progression-free survival compared to MabThera/Rituxan, when each was combined with chemotherapy.”
Follicular lymphoma is the most common indolent (slow-growing) form of non-Hodgkin lymphoma (NHL), accounting for about one in five cases of NHL. It is considered incurable and relapse is common. It is estimated that more than 75,000 people are diagnosed with follicular lymphoma each year worldwide.
Roche has announced that the US Food and Drug Administration (FDA) has approved Vabysmo (farcimab) …
Roche has announced that it has entered into a definitive agreement to acquire Telavant Holdings, …